Peptide therapy TikTok claims: separating signal from hype

What did @siamyout_official actually say?

The creator rattled off a short list of compounds, naming "GHK-Cu copper," "MOTC" (almost certainly MOTS-c, a mitochondrial peptide), and "5-amino-1MQ" alongside what sounds like "A37 on Retatru tight" which is too garbled to interpret with confidence. No specific claims about dosing, mechanisms, or outcomes were made. This is essentially a compound name-drop, not an explanation.

Because the transcript is so sparse, fact-checking individual scientific claims is limited. What we can do is evaluate whether these compounds deserve the implied legitimacy that comes from being listed together as if they form a coherent, well-supported stack. Spoiler: the evidence levels here vary wildly, and lumping them together without context is its own kind of misleading.

Does the science back this up?

GHK-Cu has the strongest research foundation of the group, though most of it is in vitro or animal-based. MOTS-c is genuinely interesting but remains largely experimental. 5-amino-1MQ is the weakest link scientifically.

GHK-Cu (copper peptide) has been studied for wound healing, skin remodeling, and anti-inflammatory signaling. Pickart and Margolina (2018, Symmetry) reviewed its role in tissue repair and gene expression modulation, noting effects on over 4,000 human genes in cell studies. That is real data, even if clinical translation is incomplete.

MOTS-c is a mitochondria-derived peptide with animal data showing improved insulin sensitivity and metabolic function. Lee et al. (2015, Cell Metabolism) identified it as a regulator of metabolic homeostasis in mice. Human trials are scarce.

5-amino-1MQ is a small molecule NNMT inhibitor, not technically a peptide, with preliminary rodent data on fat cell metabolism (Neelakantan et al., 2019, Nature Communications). Calling it a peptide and implying human efficacy is a stretch the evidence does not support yet.

What did they get wrong (or right)?

Listing these compounds together without explanation is not technically wrong, but it is irresponsible. The implied message is that this is a coherent, research-backed stack, and that framing does not hold up.

GHK-Cu gets credit: it is one of the more studied cosmetic and wound-healing peptides in the space, with legitimate published research behind it. If the creator is pointing people toward it for skin or recovery applications, the general direction is defensible.

MOTS-c is interesting but oversold across the peptide community. The leap from mouse metabolic data to human optimization is a significant one that most content creators, including this one, skip entirely.

5-amino-1MQ being listed as a peptide is factually incorrect. It is a small molecule, specifically a methyltransferase inhibitor. This is not a minor semantic error. It affects how it behaves, how it is regulated, and what the risk profile looks like. Conflating it with peptides misrepresents the compound category to viewers who may be making purchase or use decisions based on that framing.

The "A37 on Retatru tight" portion is unintelligible as transcribed and cannot be responsibly evaluated.

What should you actually know?

These compounds sit at very different points on the evidence spectrum, and none of them have FDA approval for the uses implied in peptide optimization content. That matters.

GHK-Cu is used in topical cosmetic formulations legally and has a reasonable safety profile in that context. Injectable GHK-Cu is a different regulatory category and should not be treated the same way as an over-the-counter cream.

MOTS-c is not approved for human use by any major regulatory agency. It is sold as a research chemical. Viewers should understand that "research chemical" is not a synonym for "safe to inject."

5-amino-1MQ has almost no human safety data. The rodent studies showing fat metabolism effects used controlled doses in highly monitored settings. Translating that to self-administered human use is a significant unknown risk that a six-word name-drop does nothing to address.

Anyone considering these compounds should be working with a licensed clinician who can review labs, assess contraindications, and actually monitor outcomes. A TikTok list is not a protocol.